SPY362.06-1.61 -0.44%
DIA296.62-2.62 -0.88%
IXIC12,198.74-7.11 -0.06%

Morgan Stanley Downgrades Sage Therapeutics to Equal-Weight, Announces $85 Price Target

Morgan Stanley analyst Matthew Harrison downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Equal-Weight and announces $85 price target.

· 11/16/2020 06:45
Morgan Stanley analyst Matthew Harrison downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Equal-Weight and announces $85 price target.